GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 193-204 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.

Kuryłowicz A; Czupryniak L

Jan 1, 2026

2026PubMedDirectly related

GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.

Schifano F; De Luca MA; Bonaccorso S; Arillotta D; Floresta G; Martinotti G; Papanti GD; Corkery JM; Chiappini S; Guirguis A

Jan 1, 2026Current psychiatry reports

2026PubMedDirectly related

Polish healthcare professionals' perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland.

Pucek WF; Hoffmann K; Bryl W; Kus K; Paczkowska A

Jan 1, 2026Frontiers in endocrinology

2026PubMedDirectly related

Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.

Fuentes-Mendoza JM; Concepción-Zavaleta MJ; Dongo-Dueñas LG; Jara-Pianto JMJ; Sierra-Martel JA; Medina-Angulo CA; Virú-Flores HM; Mendoza-Godoy JJ; Zavaleta-Gutiérrez FE; Paz-Ibarra J

Jan 1, 2026World journal of clinical pediatrics

2026PubMedDirectly related

Glucagon-like receptor-1 agonists and impotence: A meta-analysis.

Mirghani HO; AlQurashi AM

Jan 1, 2026World journal of methodology

2026PubMedDirectly related

GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.

Alqinai B; Gayam S; Hadam-Veverka J

Jan 1, 2026Inflammatory bowel diseases

2026PubMedDirectly related

GLP-1 receptor agonist therapy and skeletal muscle: A narrative review synthesizing adult evidence with implications for older adults.

Jagasia K; Pfeiffer AM; Vitale K

Jan 1, 2026JAR life

2026PubMedDirectly related

The effect of sex and endurance exercise training on the incretin signaling pathway in 17 rat tissues.

Jin C; Many G; Reynoso Spurrier CS; Borsellino P; Wheeler MT; Adkins JN; Snyder MP; Newgard CB; Radom-Aizik S; Cooper DM; Bodine SC; Schenk S; Lindholm ME

Jan 1, 2026Physiological genomics

2026PubMedDirectly related

Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

Ammendolia I; Mondello C; Esposito E; Calapai G; Currò M; Midiri P; Firenzuoli B; Noto A; Cancellieri A; Cardia L; Ardizzone A; Calapai F

Jan 1, 2026Naunyn-Schmiedeberg's archives of pharmacology

2026PubMedDirectly related

Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.

Baldwin K; Lau A; Ignaszewski MJ; Wong JSH; Azar P; Siu JTP

Jan 1, 2026Journal of dual diagnosis

2026PubMedDirectly related

Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia.

Prokopidis K; Cacciatore S; Anton SD; Batsis JA

Jan 1, 2026Advances in therapy

2026PubMedDirectly related

Adult Overweight and Obesity Management: Updates From the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines.

Corrado RL; Raffa SD; Bauer EM; Eisenberg D; Weare-Regales N; Antonovich N; Loblack A; Berdiel E; Kelber MS; Klimovich J; Magee JS; Sall J; Mayer SB

Jan 1, 2026Annals of internal medicine